Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Identifieur interne : 000F39 ( Main/Exploration ); précédent : 000F38; suivant : 000F40Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Auteurs : Bella Kaufman [Israël, Canada, Allemagne, Inde, Royaume-Uni, Russie, Suisse] ; John R. Mackey ; Michael R. Clemens ; Poonamalle P. Bapsy ; Ashok Vaid ; Andrew Wardley ; Sergei Tjulandin ; Michaela Jahn ; Michaela Lehle ; Andrea Feyereislova ; Cédric Revil ; Alison JonesSource :
- Journal of clinical oncology [ 0732-183X ] ; 2009.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
Abstract
Purpose TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth factor receptor 2 (HER2)/ hormone receptor-copositive metastatic breast cancer (MBC). Patients and Methods Postmenopausal women with HER2/hormone receptor-copositive MBC were randomly assigned to anastrozole (1 mg/d orally) with or without trastuzumab (4 mg/kg intravenous infusion on day 1, then 2 mg/kg every week) until progression. The primary end point was progression-free survival (PFS) in the intent-to-treat population. Results Overall, 103 patients received trastuzumab plus anastrozole; 104 received anastrozole alone. Patients in the trastuzumab plus anastrozole arm experienced significant improvements in PFS compared with patients receiving anastrozole alone (hazard ratio = 0.63; 95% CI, 0.47 to 0.84; median PFS, 4.8 v 2.4 months; log-rank P = .0016). In patients with centrally confirmed hormone receptor positivity (n = 150), median PFS was 5.6 and 3.8 months in the trastuzumab plus anastrozole and anastrozole alone arms, respectively (log-rank P = .006). Overall survival in the overall and centrally confirmed hormone receptor-positive populations showed no statistically significant treatment difference; however, 70% of patients in the anastrozole alone arm crossed over to receive trastuzumab after progression on anastrozole alone. Incidence of grade 3 and 4 adverse events was 23% and 5%, respectively, in the trastuzumab plus anastrozole arm, and 15% and 1 %, respectively, in the anastrozole alone arm; one patient in the combination arm experienced New York Heart Association class II congestive heart failure. Conclusion Trastuzumab plus anastrozole improves outcomes for patients with HER2/hormone receptor-copositive MBC compared with anastrozole alone, although adverse events and serious adverse events were more frequent with the combination.
Affiliations:
- Allemagne, Canada, Inde, Israël, Royaume-Uni, Russie, Suisse
- Angleterre, District fédéral central, Grand Londres, Grand Manchester
- Londres, Manchester, Moscou
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000601
- to stream PascalFrancis, to step Curation: 000774
- to stream PascalFrancis, to step Checkpoint: 000458
- to stream Main, to step Merge: 001014
- to stream Main, to step Curation: 000F39
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study</title>
<author><name sortKey="Kaufman, Bella" sort="Kaufman, Bella" uniqKey="Kaufman B" first="Bella" last="Kaufman">Bella Kaufman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Chaim Sheba Medical Center</s1>
<s2>Tel Hashomer</s2>
<s3>ISR</s3>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Chaim Sheba Medical Center</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Cross Cancer Institute</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Cross Cancer Institute</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Klinikum Mutterhaus der Borromaerinnen</s1>
<s2>Trier</s2>
<s3>DEU</s3>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Trier</wicri:noRegion>
<wicri:noRegion>Klinikum Mutterhaus der Borromaerinnen</wicri:noRegion>
<wicri:noRegion>Klinikum Mutterhaus der Borromaerinnen</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Kidwai Memorial Institute of Oncology, Bangalore, Rajiv Gandhi Cancer Institute</s1>
<s2>New Delhi</s2>
<s3>IND</s3>
</inist:fA14>
<country>Inde</country>
<wicri:noRegion>New Delhi</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Christie Hospital National Health Service Foundation Trust</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Royal Free Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Russian Cancer Research Center</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
</inist:fA14>
<country>Russie</country>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>F. Hoffmann-La Roche</s1>
<s2>Basel</s2>
<s3>CHE</s3>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>F. Hoffmann-La Roche</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mackey, John R" sort="Mackey, John R" uniqKey="Mackey J" first="John R." last="Mackey">John R. Mackey</name>
</author>
<author><name sortKey="Clemens, Michael R" sort="Clemens, Michael R" uniqKey="Clemens M" first="Michael R." last="Clemens">Michael R. Clemens</name>
</author>
<author><name sortKey="Bapsy, Poonamalle P" sort="Bapsy, Poonamalle P" uniqKey="Bapsy P" first="Poonamalle P." last="Bapsy">Poonamalle P. Bapsy</name>
</author>
<author><name sortKey="Vaid, Ashok" sort="Vaid, Ashok" uniqKey="Vaid A" first="Ashok" last="Vaid">Ashok Vaid</name>
</author>
<author><name sortKey="Wardley, Andrew" sort="Wardley, Andrew" uniqKey="Wardley A" first="Andrew" last="Wardley">Andrew Wardley</name>
</author>
<author><name sortKey="Tjulandin, Sergei" sort="Tjulandin, Sergei" uniqKey="Tjulandin S" first="Sergei" last="Tjulandin">Sergei Tjulandin</name>
</author>
<author><name sortKey="Jahn, Michaela" sort="Jahn, Michaela" uniqKey="Jahn M" first="Michaela" last="Jahn">Michaela Jahn</name>
</author>
<author><name sortKey="Lehle, Michaela" sort="Lehle, Michaela" uniqKey="Lehle M" first="Michaela" last="Lehle">Michaela Lehle</name>
</author>
<author><name sortKey="Feyereislova, Andrea" sort="Feyereislova, Andrea" uniqKey="Feyereislova A" first="Andrea" last="Feyereislova">Andrea Feyereislova</name>
</author>
<author><name sortKey="Revil, Cedric" sort="Revil, Cedric" uniqKey="Revil C" first="Cédric" last="Revil">Cédric Revil</name>
</author>
<author><name sortKey="Jones, Alison" sort="Jones, Alison" uniqKey="Jones A" first="Alison" last="Jones">Alison Jones</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0008046</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 10-0008046 INIST</idno>
<idno type="RBID">Pascal:10-0008046</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000601</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000774</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000458</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000458</idno>
<idno type="wicri:doubleKey">0732-183X:2009:Kaufman B:trastuzumab:plus:anastrozole</idno>
<idno type="wicri:Area/Main/Merge">001014</idno>
<idno type="wicri:Area/Main/Curation">000F39</idno>
<idno type="wicri:Area/Main/Exploration">000F39</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study</title>
<author><name sortKey="Kaufman, Bella" sort="Kaufman, Bella" uniqKey="Kaufman B" first="Bella" last="Kaufman">Bella Kaufman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Chaim Sheba Medical Center</s1>
<s2>Tel Hashomer</s2>
<s3>ISR</s3>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Chaim Sheba Medical Center</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Cross Cancer Institute</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Cross Cancer Institute</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Klinikum Mutterhaus der Borromaerinnen</s1>
<s2>Trier</s2>
<s3>DEU</s3>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Trier</wicri:noRegion>
<wicri:noRegion>Klinikum Mutterhaus der Borromaerinnen</wicri:noRegion>
<wicri:noRegion>Klinikum Mutterhaus der Borromaerinnen</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Kidwai Memorial Institute of Oncology, Bangalore, Rajiv Gandhi Cancer Institute</s1>
<s2>New Delhi</s2>
<s3>IND</s3>
</inist:fA14>
<country>Inde</country>
<wicri:noRegion>New Delhi</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Christie Hospital National Health Service Foundation Trust</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Royal Free Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Russian Cancer Research Center</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
</inist:fA14>
<country>Russie</country>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>F. Hoffmann-La Roche</s1>
<s2>Basel</s2>
<s3>CHE</s3>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>F. Hoffmann-La Roche</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mackey, John R" sort="Mackey, John R" uniqKey="Mackey J" first="John R." last="Mackey">John R. Mackey</name>
</author>
<author><name sortKey="Clemens, Michael R" sort="Clemens, Michael R" uniqKey="Clemens M" first="Michael R." last="Clemens">Michael R. Clemens</name>
</author>
<author><name sortKey="Bapsy, Poonamalle P" sort="Bapsy, Poonamalle P" uniqKey="Bapsy P" first="Poonamalle P." last="Bapsy">Poonamalle P. Bapsy</name>
</author>
<author><name sortKey="Vaid, Ashok" sort="Vaid, Ashok" uniqKey="Vaid A" first="Ashok" last="Vaid">Ashok Vaid</name>
</author>
<author><name sortKey="Wardley, Andrew" sort="Wardley, Andrew" uniqKey="Wardley A" first="Andrew" last="Wardley">Andrew Wardley</name>
</author>
<author><name sortKey="Tjulandin, Sergei" sort="Tjulandin, Sergei" uniqKey="Tjulandin S" first="Sergei" last="Tjulandin">Sergei Tjulandin</name>
</author>
<author><name sortKey="Jahn, Michaela" sort="Jahn, Michaela" uniqKey="Jahn M" first="Michaela" last="Jahn">Michaela Jahn</name>
</author>
<author><name sortKey="Lehle, Michaela" sort="Lehle, Michaela" uniqKey="Lehle M" first="Michaela" last="Lehle">Michaela Lehle</name>
</author>
<author><name sortKey="Feyereislova, Andrea" sort="Feyereislova, Andrea" uniqKey="Feyereislova A" first="Andrea" last="Feyereislova">Andrea Feyereislova</name>
</author>
<author><name sortKey="Revil, Cedric" sort="Revil, Cedric" uniqKey="Revil C" first="Cédric" last="Revil">Cédric Revil</name>
</author>
<author><name sortKey="Jones, Alison" sort="Jones, Alison" uniqKey="Jones A" first="Alison" last="Jones">Alison Jones</name>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Advanced stage</term>
<term>Anastrozole</term>
<term>Antineoplastic agent</term>
<term>Breast cancer</term>
<term>Cancerology</term>
<term>Comparative study</term>
<term>Female</term>
<term>Hormonal receptor</term>
<term>Human</term>
<term>Human Epidermal growth factor Receptor 2</term>
<term>Metastasis</term>
<term>Phase III trial</term>
<term>Postmenopause</term>
<term>Randomization</term>
<term>Trastuzumab</term>
<term>Treatment</term>
<term>Woman</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Anastrozole</term>
<term>Trastuzumab</term>
<term>Etude comparative</term>
<term>Métastase</term>
<term>Traitement</term>
<term>Postménopause</term>
<term>Cancer du sein</term>
<term>Homme</term>
<term>Femelle</term>
<term>Essai clinique phase III</term>
<term>Adulte</term>
<term>Femme</term>
<term>Récepteur hormonal</term>
<term>Stade avancé</term>
<term>Randomisation</term>
<term>Cancérologie</term>
<term>Anticancéreux</term>
<term>Récepteur HER2</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Adulte</term>
<term>Femme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth factor receptor 2 (HER2)/ hormone receptor-copositive metastatic breast cancer (MBC). Patients and Methods Postmenopausal women with HER2/hormone receptor-copositive MBC were randomly assigned to anastrozole (1 mg/d orally) with or without trastuzumab (4 mg/kg intravenous infusion on day 1, then 2 mg/kg every week) until progression. The primary end point was progression-free survival (PFS) in the intent-to-treat population. Results Overall, 103 patients received trastuzumab plus anastrozole; 104 received anastrozole alone. Patients in the trastuzumab plus anastrozole arm experienced significant improvements in PFS compared with patients receiving anastrozole alone (hazard ratio = 0.63; 95% CI, 0.47 to 0.84; median PFS, 4.8 v 2.4 months; log-rank P = .0016). In patients with centrally confirmed hormone receptor positivity (n = 150), median PFS was 5.6 and 3.8 months in the trastuzumab plus anastrozole and anastrozole alone arms, respectively (log-rank P = .006). Overall survival in the overall and centrally confirmed hormone receptor-positive populations showed no statistically significant treatment difference; however, 70% of patients in the anastrozole alone arm crossed over to receive trastuzumab after progression on anastrozole alone. Incidence of grade 3 and 4 adverse events was 23% and 5%, respectively, in the trastuzumab plus anastrozole arm, and 15% and 1 %, respectively, in the anastrozole alone arm; one patient in the combination arm experienced New York Heart Association class II congestive heart failure. Conclusion Trastuzumab plus anastrozole improves outcomes for patients with HER2/hormone receptor-copositive MBC compared with anastrozole alone, although adverse events and serious adverse events were more frequent with the combination.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Canada</li>
<li>Inde</li>
<li>Israël</li>
<li>Royaume-Uni</li>
<li>Russie</li>
<li>Suisse</li>
</country>
<region><li>Angleterre</li>
<li>District fédéral central</li>
<li>Grand Londres</li>
<li>Grand Manchester</li>
</region>
<settlement><li>Londres</li>
<li>Manchester</li>
<li>Moscou</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Bapsy, Poonamalle P" sort="Bapsy, Poonamalle P" uniqKey="Bapsy P" first="Poonamalle P." last="Bapsy">Poonamalle P. Bapsy</name>
<name sortKey="Clemens, Michael R" sort="Clemens, Michael R" uniqKey="Clemens M" first="Michael R." last="Clemens">Michael R. Clemens</name>
<name sortKey="Feyereislova, Andrea" sort="Feyereislova, Andrea" uniqKey="Feyereislova A" first="Andrea" last="Feyereislova">Andrea Feyereislova</name>
<name sortKey="Jahn, Michaela" sort="Jahn, Michaela" uniqKey="Jahn M" first="Michaela" last="Jahn">Michaela Jahn</name>
<name sortKey="Jones, Alison" sort="Jones, Alison" uniqKey="Jones A" first="Alison" last="Jones">Alison Jones</name>
<name sortKey="Lehle, Michaela" sort="Lehle, Michaela" uniqKey="Lehle M" first="Michaela" last="Lehle">Michaela Lehle</name>
<name sortKey="Mackey, John R" sort="Mackey, John R" uniqKey="Mackey J" first="John R." last="Mackey">John R. Mackey</name>
<name sortKey="Revil, Cedric" sort="Revil, Cedric" uniqKey="Revil C" first="Cédric" last="Revil">Cédric Revil</name>
<name sortKey="Tjulandin, Sergei" sort="Tjulandin, Sergei" uniqKey="Tjulandin S" first="Sergei" last="Tjulandin">Sergei Tjulandin</name>
<name sortKey="Vaid, Ashok" sort="Vaid, Ashok" uniqKey="Vaid A" first="Ashok" last="Vaid">Ashok Vaid</name>
<name sortKey="Wardley, Andrew" sort="Wardley, Andrew" uniqKey="Wardley A" first="Andrew" last="Wardley">Andrew Wardley</name>
</noCountry>
<country name="Israël"><noRegion><name sortKey="Kaufman, Bella" sort="Kaufman, Bella" uniqKey="Kaufman B" first="Bella" last="Kaufman">Bella Kaufman</name>
</noRegion>
</country>
<country name="Canada"><noRegion><name sortKey="Kaufman, Bella" sort="Kaufman, Bella" uniqKey="Kaufman B" first="Bella" last="Kaufman">Bella Kaufman</name>
</noRegion>
</country>
<country name="Allemagne"><noRegion><name sortKey="Kaufman, Bella" sort="Kaufman, Bella" uniqKey="Kaufman B" first="Bella" last="Kaufman">Bella Kaufman</name>
</noRegion>
</country>
<country name="Inde"><noRegion><name sortKey="Kaufman, Bella" sort="Kaufman, Bella" uniqKey="Kaufman B" first="Bella" last="Kaufman">Bella Kaufman</name>
</noRegion>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Kaufman, Bella" sort="Kaufman, Bella" uniqKey="Kaufman B" first="Bella" last="Kaufman">Bella Kaufman</name>
</region>
<name sortKey="Kaufman, Bella" sort="Kaufman, Bella" uniqKey="Kaufman B" first="Bella" last="Kaufman">Bella Kaufman</name>
</country>
<country name="Russie"><region name="District fédéral central"><name sortKey="Kaufman, Bella" sort="Kaufman, Bella" uniqKey="Kaufman B" first="Bella" last="Kaufman">Bella Kaufman</name>
</region>
</country>
<country name="Suisse"><noRegion><name sortKey="Kaufman, Bella" sort="Kaufman, Bella" uniqKey="Kaufman B" first="Bella" last="Kaufman">Bella Kaufman</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F39 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F39 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Rhénanie |area= UnivTrevesV1 |flux= Main |étape= Exploration |type= RBID |clé= Pascal:10-0008046 |texte= Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study }}
This area was generated with Dilib version V0.6.31. |